ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARMP Armata Pharmaceuticals Inc

2.76
0.2292 (9.06%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 9,511
Bid Price
Ask Price
News -
Day High 2.80

Low
1.0701

52 Week Range

High
5.2565

Day Low 2.41
Share Name Share Symbol Market Stock Type
Armata Pharmaceuticals Inc ARMP AMEX Common Stock
  Price Change Price Change % Share Price Last Trade
0.2292 9.06% 2.76 19:00:00
Open Price Low Price High Price Close Price Previous Close
2.53 2.41 2.80 2.76 2.5308
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
232 9,511 US$ 2.63 US$ 25,001 - 1.0701 - 5.2565
Last Trade Type Quantity Price Currency
19:00:00 100 US$ 2.76 USD

Armata Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 36.15M - 4.53M -69.05M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Armata Pharmaceuticals News

Date Time Source News Article
3/04/202416:35Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of..
3/04/202415:03Edgar (US Regulatory)Form 8-K - Current report
1/23/202415:17Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee..
12/26/202320:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/26/202320:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/26/202320:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/26/202320:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/26/202320:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/26/202320:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/26/202320:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/26/202320:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/15/202316:24Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ARMP Message Board. Create One! See More Posts on ARMP Message Board See More Message Board Posts

Historical ARMP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.552.852.352.568,1960.218.24%
1 Month4.184.452.353.1813,091-1.42-33.97%
3 Months3.854.482.353.5515,924-1.09-28.31%
6 Months2.004.481.933.2516,5370.7638.00%
1 Year1.575.25651.07012.6655,8351.1975.80%
3 Years4.286.490.83113.0728,591-1.52-35.51%
5 Years4.9010.480.83113.7138,307-2.14-43.67%

Armata Pharmaceuticals Description

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Your Recent History

Delayed Upgrade Clock